Viemed Healthcare (NASDAQ:VMD) Releases Quarterly Earnings Results

Viemed Healthcare (NASDAQ:VMD) announced its quarterly earnings results on Tuesday. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03), FiscalAI reports. Viemed Healthcare had a net margin of 5.53% and a return on equity of 10.72%. The business had revenue of $75.41 million during the quarter, compared to analysts’ expectations of $74.40 million.

Viemed Healthcare Stock Up 2.3%

Viemed Healthcare stock traded up $0.22 during midday trading on Tuesday, hitting $9.70. 252,431 shares of the company were exchanged, compared to its average volume of 246,049. The company has a market cap of $373.26 million, a PE ratio of 26.22 and a beta of 1.15. Viemed Healthcare has a fifty-two week low of $5.93 and a fifty-two week high of $10.18. The company’s fifty day moving average price is $9.31 and its 200-day moving average price is $7.94. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.18 and a quick ratio of 1.06.

Insider Activity

In other news, President Michael Moore sold 65,000 shares of Viemed Healthcare stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $8.77, for a total transaction of $570,050.00. Following the sale, the president owned 1,585,812 shares in the company, valued at $13,907,571.24. This trade represents a 3.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 136,802 shares of company stock worth $1,237,976 in the last 90 days. Company insiders own 20.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Kemnay Advisory Services Inc. purchased a new position in shares of Viemed Healthcare in the fourth quarter valued at $46,000. Quarry LP purchased a new position in shares of Viemed Healthcare in the third quarter valued at $48,000. AQR Capital Management LLC purchased a new position in shares of Viemed Healthcare in the first quarter valued at $90,000. MetLife Investment Management LLC boosted its stake in shares of Viemed Healthcare by 52.7% in the fourth quarter. MetLife Investment Management LLC now owns 18,565 shares of the company’s stock valued at $138,000 after purchasing an additional 6,408 shares during the period. Finally, Invesco Ltd. boosted its stake in shares of Viemed Healthcare by 25.5% in the second quarter. Invesco Ltd. now owns 18,652 shares of the company’s stock valued at $129,000 after purchasing an additional 3,795 shares during the period. 74.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Zacks Research raised shares of Viemed Healthcare to a “hold” rating in a research report on Thursday, January 8th. Wall Street Zen upgraded shares of Viemed Healthcare from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. Two investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Viemed Healthcare has an average rating of “Hold”.

Viemed Healthcare Company Profile

Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.